Free tool
FAERS Monitor: Ekterly
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 219301 or its brand name (Ekterly, Sebetralstat). Reports on generic versions are filed under their own applications.
Reports
539
Serious
191
35% of reports
Hospitalization
95
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hereditary angioedema218
- drug ineffective102
- incorrect dose administered47
- headache36
- stress30
- product dose omission issue22
- weight increased22
- weight decreased19
- vomiting18
- nausea15
- off label use14
- dizziness13
- fall13
- malaise13
- pruritus13
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 8 |
| 2025 | 82 |
| 2026 | 443 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,620 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hereditary angioedemaSignal | 218 | 809.1 | 729.0 | 171,679 |
| stressSignal | 30 | 16.2 | 11.5 | 415 |
| incorrect dose administeredSignal | 47 | 8.0 | 6.1 | 286 |
| weight increasedSignal | 22 | 3.8 | 2.5 | 44 |
| drug ineffectiveSignal | 102 | 3.0 | 2.5 | 145 |
| product dose omission issueSignal | 22 | 2.9 | 1.9 | 26 |
| weight decreasedSignal | 19 | 2.7 | 1.7 | 18 |
| headacheSignal | 36 | 2.2 | 1.6 | 24 |
| fall | 13 | 1.5 | 0.9 | 2 |
| vomiting | 18 | 1.5 | 0.9 | 3 |
| pruritus | 13 | 1.3 | 0.8 | 1 |
| malaise | 13 | 1.2 | 0.7 | 0 |
| dizziness | 13 | 1.0 | 0.6 | 0 |
| nausea | 15 | 0.7 | 0.4 | 1 |
| off label use | 14 | 0.6 | 0.4 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.